After many years of slow progress, drug companies are finally seeing results in the search for Alzheimer's treatment. FDA panel voted unanimously in favor of Eli Lilly's donanemab, stating benefits outweigh risks.
Eli Lilly utilized a new method to identify progressive Alzheimer's patients with PET brain scans for tau protein. The trial also allowed some to stop treatment if amyloid plaques were cleared, resembling cancer treatment approach.
[
add
]
[
|
|
...
]